Komori
Earnings presentation4151Kyowa Kirin Co.,Ltd.Pharmaceuticals

Supplementary Financial Results Materials — Second Quarter (Interim Period) Financial Results for the Fiscal Year Ending December 2026

In the first half of the fiscal year ending December 2026, revenue, core operating profit and profit for the period exceeded the year-earlier period. Revenue and core operating profit reached 51% of the full-year forecasts. Revenue by region and product, investment, headcount and the development pipeline were also updated.

Worth reading
52Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
330
¥100 million (year-on-year increase in revenue)
Wording
Avoiding a definitive answer
How definitive the wording is.

Contents of this document

Supplementary materials to the earnings reportSecond quarter (interim period) of the fiscal year ending December 20266 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥2,636 100 million+14.0%
Operating profit¥661 100 million +80.0%core operating profit
Ordinary income¥375 100 million +70.0%profit before tax for the quarter
Net income¥306 100 million +88.0%profit for the year
Selling, general and administrative expenses¥848 100 million
Gross Profit Margin
Rate74.8%
Operating profit margin
Rate25.1% (core operating margin)
Results for the three months of the current quarter
Revenue
¥1,452 100 million+15.0%
Gross profit
¥1,090 100 million+23.0%
Selling, general and administrative expenses
¥437 100 million +12.0%expense
Research and development costs
¥192 100 million -20.0%expense
Core operating profit
¥461 100 million+80.0%
Profit before quarterly income taxes
¥235 100 million+67.0%
Quarterly profit
¥186 100 million+83.0%
Full-year earnings forecast
Revenue
¥5,200 100 million
Gross profit
¥3,880 100 million
Selling, general and administrative expenses
¥1,630 100 million expense
Research and development costs
¥950 100 million expense
Core operating profit
¥1,300 100 million
Income before taxes
¥950 100 million
Profit for the period
¥750 100 million
Core profit for the period
¥1,030 100 million
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。
Revenue51%
Cost of sales50%
Gross profit51%
Selling, general and administrative expenses52%
Research and development costs49%
Core operating profit51%
Income before taxes39%
Income tax expense34%
Profit for the period41%
Core profit for the period52%
Revenue by regional headquarters company
Japan49%
North America49%
EMEA55%
Other52%
Revenue by product
Products and merchandise50%
Crysvita50%
Poteligeo47%
Libmeldy／Lenmeldy48%
Nourianz58%
Fozebel38%
Duvroq51%
Nesp50%
Darbepoetin alfa injection syringe "KKF"49%
G-Lasta44%
Romiplate55%
Orkedia48%
Rituximab BS "KKF"55%
Nourianz56%
Hyrloz52%
Technology income53%
What the company explained in this material
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Exchange rate
US dollars¥150/USD
British pound¥205/GBP
Euro¥180/EUR
Key KPIsA metric the company considers important as a management benchmark.
  • ROE7.7 %
  • ROE (three-year average)8.3 %
  • DOE3.8 %
  • Overseas Revenue Mix78 %
    Year on year against the same period last year+5 percentage points
  • Cash flow from operating activities¥813 100 million
    Year on year against the same period last year+415.0%
Segment results
Revenue by regional headquarters company
  • Japan¥549 100 million-6.0%
  • North America¥1,033 100 million+17.0%
  • EMEA¥433 100 million+17.0%
  • Other¥621 100 million+33.0%
Financial targets
ROE
Actual results7.7 %
Full-year outlook8.2 %
ROE (three-year average)
Actual results8.3 %
Full-year outlook7.7 %
DOE
Actual results3.8 %
Full-year outlook4.1 %
PolicyProgressive dividends
Number of employees
Number of Employees5,173 people
Change during the period-316 people
Capital expenditures
¥183 100 million total capital expenditure and investment in intangible assets, January–June 2026
Contents of this document
ItemDetails
Document typeSupplementary materials to the earnings report
Fiscal Period CoveredSecond quarter (interim period) of the fiscal year ending December 2026
Net Sales¥2,636 100 million (YoY +14.0%)
Operating profit¥661 100 million (core operating profit) (YoY +80.0%)
Ordinary income¥375 100 million (profit before tax for the quarter) (YoY +70.0%)
Net income¥306 100 million (profit for the year) (YoY +88.0%)
Gross Profit MarginRate 74.8% / Year-on-year change (points) Not disclosed
Operating profit marginRate 25.1% (core operating margin) / Year-on-year change (points) Not disclosed
Selling, general and administrative expenses¥848 100 million
Results for the three months of the current quarterRevenue ¥1,452 100 million (YoY +15.0%) / Gross profit ¥1,090 100 million (YoY +23.0%) / Selling, general and administrative expenses ¥437 100 million (expense) (YoY +12.0%) / Research and development costs ¥192 100 million (expense) (YoY -20.0%) / Core operating profit ¥461 100 million (YoY +80.0%) / Profit before quarterly income taxes ¥235 100 million (YoY +67.0%) / Quarterly profit ¥186 100 million (YoY +83.0%)
Full-year earnings forecastRevenue ¥5,200 100 million / Gross profit ¥3,880 100 million / Selling, general and administrative expenses ¥1,630 100 million (expense) / Research and development costs ¥950 100 million (expense) / Core operating profit ¥1,300 100 million / Income before taxes ¥950 100 million / Profit for the period ¥750 100 million / Core profit for the period ¥1,030 100 million
Progress against full-year forecastRevenue 51% / Cost of sales 50% / Gross profit 51% / Selling, general and administrative expenses 52% / Research and development costs 49% / Core operating profit 51% / Income before taxes 39% / Income tax expense 34% / Profit for the period 41% / Core profit for the period 52% / Revenue by regional headquarters company Japan 49% / North America 49% / EMEA 55% / Other 52% / Revenue by product Products and merchandise 50% / Crysvita 50% / Poteligeo 47% / Libmeldy／Lenmeldy 48% / Nourianz 58% / Fozebel 38% / Duvroq 51% / Nesp 50% / Darbepoetin alfa injection syringe "KKF" 49% / G-Lasta 44% / Romiplate 55% / Orkedia 48% / Rituximab BS "KKF" 55% / Nourianz 56% / Hyrloz 52% / Technology income 53%
Segment resultsRevenue by regional headquarters company Japan ¥549 100 million (YoY -6.0%), North America ¥1,033 100 million (YoY +17.0%), EMEA ¥433 100 million (YoY +17.0%), Other ¥621 100 million (YoY +33.0%) / Profit Not disclosed
Key KPIsIndicator name ROE / Value 7.7 % / Year on year against the same period last year Not disclosed, Indicator name ROE (three-year average) / Value 8.3 % / Year on year against the same period last year Not disclosed, Indicator name DOE / Value 3.8 % / Year on year against the same period last year Not disclosed, Indicator name Overseas Revenue Mix / Value 78 % / Year on year against the same period last year +5 percentage points, Indicator name Cash flow from operating activities / Value ¥813 100 million / Year on year against the same period last year ¥415 100 million
Number of employeesNumber of Employees 5,173 people / Change during the period -316 people
Assumptions Underlying the Business OutlookExchange rate US dollars ¥150/USD / British pound ¥205/GBP / Euro ¥180/EUR
Financial targetsROE Actual results 7.7 % / Full-year outlook 8.2 % / ROE (three-year average) Actual results 8.3 % / Full-year outlook 7.7 % / DOE Actual results 3.8 % / Full-year outlook 4.1 % / Policy Progressive dividends
Capital expenditures¥183 100 million (total capital expenditure and investment in intangible assets, January–June 2026)
Items this document does not state (13)
Self-assessment against the planBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsAnnual DividendPayout ratioAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&ANew initiatives

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

No explanation is provided for the reasons behind the changes in financial performance. The figures show higher revenue in North America, EMEA and other regions, as well as from Crysvita, technical income and other sources, but the company does not expressly identify these as the reasons for the revenue increase in narrative form.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Supplementary Financial Results Materials — Second Quarter (Interim Period) Financial Results for the Fiscal Year Ending December 2026 | Kyowa Kirin Co.,Ltd. (4151) timely disclosure | Komori